159 related articles for article (PubMed ID: 10091802)
21. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
Gronlund B; Hansen HH; Høgdall C; Engelholm SA
Cancer; 2002 Oct; 95(8):1656-62. PubMed ID: 12365013
[TBL] [Abstract][Full Text] [Related]
22. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen.
Couldwell WT; Hinton DR; Surnock AA; DeGiorgio CM; Weiner LP; Apuzzo ML; Masri L; Law RE; Weiss MH
Clin Cancer Res; 1996 Apr; 2(4):619-22. PubMed ID: 9816211
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group.
Macdonald D; Cairncross G; Stewart D; Forsyth P; Sawka C; Wainman N; Eisenhauer E
Ann Oncol; 1996 Feb; 7(2):205-7. PubMed ID: 8777179
[TBL] [Abstract][Full Text] [Related]
24. A phase 1/2 study of orally administered synthetic hypericin for treatment of recurrent malignant gliomas.
Couldwell WT; Surnock AA; Tobia AJ; Cabana BE; Stillerman CB; Forsyth PA; Appley AJ; Spence AM; Hinton DR; Chen TC
Cancer; 2011 Nov; 117(21):4905-15. PubMed ID: 21456013
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
Turner CD; Gururangan S; Eastwood J; Bottom K; Watral M; Beason R; McLendon RE; Friedman AH; Tourt-Uhlig S; Miller LL; Friedman HS
Neuro Oncol; 2002 Apr; 4(2):102-8. PubMed ID: 11916501
[TBL] [Abstract][Full Text] [Related]
26. Profound thrombocytopenia in previously treated patients with recurrent ovarian carcinoma receiving topotecan.
Cass I; Kuo DY; Fields AL; Runowicz CD; Goldberg GL
Gynecol Oncol; 1998 May; 69(2):175-8. PubMed ID: 9600828
[No Abstract] [Full Text] [Related]
27. A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study.
Robins HI; Chang SM; Prados MD; Yung WK; Hess K; Schiff D; Greenberg H; Fink K; Nicolas K; Kuhn JG; Cloughesy T; Junck L; Mehta M
Neuro Oncol; 2002 Apr; 4(2):109-14. PubMed ID: 11916502
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
Cloughesy TF; Wen PY; Robins HI; Chang SM; Groves MD; Fink KL; Junck L; Schiff D; Abrey L; Gilbert MR; Lieberman F; Kuhn J; DeAngelis LM; Mehta M; Raizer JJ; Yung WK; Aldape K; Wright J; Lamborn KR; Prados MD
J Clin Oncol; 2006 Aug; 24(22):3651-6. PubMed ID: 16877733
[TBL] [Abstract][Full Text] [Related]
29. A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma.
Pipas JM; Meyer LP; Rhodes CH; Cromwell LD; McDonnell CE; Kingman LS; Rigas JR; Fadul CE
J Neurooncol; 2005 Feb; 71(3):301-5. PubMed ID: 15735921
[TBL] [Abstract][Full Text] [Related]
30. A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma.
Tang P; Roldan G; Brasher PM; Fulton D; Roa W; Murtha A; Cairncross JG; Forsyth PA
J Neurooncol; 2006 Jul; 78(3):311-6. PubMed ID: 16710748
[TBL] [Abstract][Full Text] [Related]
31. A phase II study of metronomic oral topotecan for recurrent childhood brain tumors.
Minturn JE; Janss AJ; Fisher PG; Allen JC; Patti R; Phillips PC; Belasco JB
Pediatr Blood Cancer; 2011 Jan; 56(1):39-44. PubMed ID: 21108437
[TBL] [Abstract][Full Text] [Related]
32. Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol.
da Fonseca CO; Linden R; Futuro D; Gattass CR; Quirico-Santos T
Arch Immunol Ther Exp (Warsz); 2008; 56(4):267-76. PubMed ID: 18726148
[TBL] [Abstract][Full Text] [Related]
33. Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas.
da Fonseca CO; Schwartsmann G; Fischer J; Nagel J; Futuro D; Quirico-Santos T; Gattass CR
Surg Neurol; 2008 Sep; 70(3):259-66; discussion 266-7. PubMed ID: 18295834
[TBL] [Abstract][Full Text] [Related]
34. Evolving strategies: future treatment of glioblastoma.
Chamberlain M
Expert Rev Neurother; 2011 Apr; 11(4):519-32. PubMed ID: 21469925
[TBL] [Abstract][Full Text] [Related]
35. Carboplatin chemotherapy in patients with recurrent high-grade glioma.
Murray LJ; Bridgewater CH; Levy D
Clin Oncol (R Coll Radiol); 2011 Feb; 23(1):55-61. PubMed ID: 20952169
[TBL] [Abstract][Full Text] [Related]
36. Topotecan for the treatment of recurrent or progressive central nervous system tumors - a pediatric oncology group phase II study.
Kadota RP; Stewart CF; Horn M; Kuttesch JF; Burger PC; Kepner JL; Kun LE; Friedman HS; Heideman RL
J Neurooncol; 1999 May; 43(1):43-7. PubMed ID: 10448870
[TBL] [Abstract][Full Text] [Related]
37. Early Cerebral Blood Volume Changes Predict Progression After Convection-Enhanced Delivery of Topotecan for Recurrent Malignant Glioma.
Surapaneni K; Kennedy BC; Yanagihara TK; DeLaPaz R; Bruce JN
World Neurosurg; 2015 Jul; 84(1):163-72. PubMed ID: 25772608
[TBL] [Abstract][Full Text] [Related]
38. Long-term outcome in patients with recurrent malignant glioma treated with Perillyl alcohol inhalation.
DA Fonseca CO; Teixeira RM; Silva JC; DE Saldanha DA Gama Fischer J; Meirelles OC; Landeiro JA; Quirico-Santos T
Anticancer Res; 2013 Dec; 33(12):5625-31. PubMed ID: 24324108
[TBL] [Abstract][Full Text] [Related]
39. Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma.
Phuphanich S; Carson KA; Grossman SA; Lesser G; Olson J; Mikkelsen T; Desideri S; Fisher JD;
Neuro Oncol; 2008 Aug; 10(4):617-23. PubMed ID: 18477765
[TBL] [Abstract][Full Text] [Related]
40. [Dibutyryl cyclic adenosine monophosphate (DBc-AMP) in the treatment of recurrent malignant gliomas--report of 7 patients].
Zhu FQ; Du ZW; Bao YD
Zhonghua Zhong Liu Za Zhi; 1987 Nov; 9(6):460-2, 21. PubMed ID: 2838244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
